Silvia Delgado
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $17,034 of the $28,002 with a category attached, or 60.8%. Novartis accounts for 69.9% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $19,078 and has fallen 98.9% since, to $210 in 2025.
Across 55 payments — averaging $509.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$20K
- Novartis Pharma AG$6K
- Sanofi$2K
- Biogen$254
- AstraZeneca$145
- Genentech USA, Inc.$120
- plus $237 from 7 others
Across 110 payments — averaging $100,091 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$10.8M
- EMD Serono, Inc.$164K
- Biogen$35K
- Janssen Research & Development, LLC$27K
- AbbVie$2K
- Novartis Pharma AG$1K
- plus $850 from 1 others
What the payments were for
- Consulting fees$17,03461%
- Travel & lodging$7,00025%
- Food & beverage$1,9287%
- Education$400%
- Charitable contribution$2,0007%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 24 | $19,563 |
| Novartis Pharma AG | 5 | $5,598 |
| Sanofi | 3 | $2,084 |
| Biogen | 6 | $254 |
| AstraZeneca | 3 | $145 |
| Genentech USA, Inc. | 5 | $120 |
| Bristol Myers Squibb | 3 | $71 |
| EMD Serono, Inc. | 1 | $40 |
| TG Therapeutics, Inc. | 1 | $37 |
| Lundbeck LLC | 1 | $33 |
| Cycle Pharmaceuticals Inc | 1 | $23 |
| AbbVie | 1 | $22 |
| Lilly USA, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MAYZENT$8,685
- KESIMPTA$4,894
- OMB157G_ARZERRA_HEMATOLOGY$4,409
- TYSABRI$117
- SOLIRIS$117
How this compares
$28,002 in reported general payments places this provider in the 85th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 26 | $249,904 |
| Teriflunomide | 15 | $6,490 |
| Dimethyl Fumarate | 36 | $5,665 |
| Baclofen | 70 | $1,247 |
| Tizanidine Hcl | 13 | $175 |
| Diazepam | 13 | $31 |
Paid to pharmacies, not to this prescriber.
Other neurology in Miami
- Diego Torres-RussottoMiami$652K
- Bruno GalloMiami$313K
- Brad HerskowitzMiami$273K
- Flavia NelsonMiami$264K
- Corneliu LucaMiami$257K
- Kottil RammohanMiami$176K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.